| Project/Area Number |
17390127
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (B)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Bacteriology (including Mycology)
|
|---|
| Research Institution | OKAYAMA UNIVERSITY |
|---|
Principal Investigator |
OGUMA Keiji Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Professor, 大学院医歯薬学総合研究科, 教授 (00002262)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
YOKOTA Kenji Okayama University Medical School, Faculty of Health Sciences, Associate Professor, 医学部, 助教授 (00243460)
AYADA Kiyoshi Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Research Associate, 大学院医歯薬学総合研究科, 助手 (00379835)
KOUICHI Takeshi Obihiro University of Agriculture and veterinary Medicine, Faculty of Animal Husbandry School of Veterinary Medicine, Professor, 畜産学部, 教授 (50396339)
ARIMITSU Hideyuki Fujita Health University, Faculty of Medicine, Lecturer, 医学部, 講師 (40367701)
|
|---|
| Project Period (FY) |
2005 – 2006
|
| Project Status |
Completed (Fiscal Year 2006)
|
| Budget Amount *help |
¥14,600,000 (Direct Cost: ¥14,600,000)
Fiscal Year 2006: ¥6,000,000 (Direct Cost: ¥6,000,000)
Fiscal Year 2005: ¥8,600,000 (Direct Cost: ¥8,600,000)
|
|---|
| Keywords | bacteria / infectious disease / protein / medicine, welfare / food |
|---|
| Research Abstract |
1. Development of vaccine and immuno-strip for detecting toxin
In order to prepare the safe and effective type C and D vaccines for animal botulism, the heavy chains (100 kDa) and their C-terminal (Hc, 50 kDa) and N-terminal (Hn, 50 kDa) half fragments were prepared as GST fusion proteins. Production level of Hc and Hn was quite higher than that of H. H and He showed good vaccine effects but that of Hn was quite low. GST fused-or GST-eliminated He preparation showed similar vaccine effect. Therfore, it was concluded that He with or without GST can be used as commercially effective vaccine. Immuno-strip method was prepared using polyclonal antisera against A, B, E, and F neurotoxins. They could detect approximately 1 ng of each toxin.
2. Development of neurotoxin preparations for treating dystonia
We found that HAI and HA3b, which are the subcomponents of HA, have adjuvant activity. Therefore, we tried to treat the patients with the neurotoxins rather than the progenitor toxins. We found that Type A and B neurotoxins can easily be purified by using a lactose gel column, and that they can be stocked in a deep freezer without reducing the toxin activity by mixing with 0.05% albumin (for type B) or 0.05% albumin plus 1% terehalose (for type A). When this preparation was used for the treatment of 18 patients with urinary incontinence caused by refractory idiopathic and neurogenic detrusor overactivity, 16 patients showed excellent improvement; it started within 1 week after injection in most cases and lasted 3 to 12 months.
|
